Nephrology

Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.

ADA 2021: The investigational exendin-4-based GLP-1 RA was associated with a 27% decrease in risk for a CV event and a 32% reduction in risk for CKD progression.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not GLP-1 receptor agonists were on board at study baseline.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.

The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.

New research proposes pathophysiology-based subphenotyping of individuals at increased risk for T2D; 6 are suggested to help refine screening, prevention, and treatment.

SGLT-2 inhibitor investigator Mikhail Kosiborod, MD, answers questions about patient selection for the class of drugs, now with approval to treat much more than type 2 diabetes.

CKD IQ Test Preview: When should you suspect kidney disease? What measure is used to define chronic kidney disease? What UACR test result indicates albuminuria? Good luck.

Mikhail Kosiborod, MD, a lead investigator for clinical trials of SGLT2 inhibitors, traces the class history from antidiabetic agents to guideline-recommended multidisease treatments.

Most patients with chronic kidney disease are treated in primary care where the primary goal is twofold: slow progression and prevent complications. Find essentials of both, here.

ACC.2021: A new analysis of FIDELIO-DKD found patients with chronic kidney disease and type 2 diabetes were about 30% less likely to develop atrial fibrillation vs those treated with placebo.

Early detection of chronic kidney disease in primary care provides a significant opportunity to avoid complications and slow the loss of renal function. Topline guidance, here.

Primary care clinicians have an essential role in the diagnosis and treatment of chronic kidney disease. Click through a review of the basics.

The 2020 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline integrates new treatments and practices with existing management strategies for CKD patients with diabetes.

Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.

ACP: Clyde W Yancy, MD, gave a comprehensive update on a year's worth of pivotal science in treatment of heart failure. Here are the highlights.

Video: George Bakris, MD says over the next 3 years there is going to be an "explosion" in the number of studies we see in heart failure, diabetic kidney disease, and CV risk in general.

The most popular features in preventive cardiology this year were interviews with thought leaders on management of diabetes, hypertension, and hypercholesterolemia.

Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.

Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.

DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.

AHA: DAPD-CKD investigator Prof John McMurray talks to Patient Care about the “revolutionary” findings he will highlight at the AHA sessions on opening day.

Finerenone, a non-steroidal, selective MRA, has distinct advantages over current treatments for diabetic kidney disease. Dr Bakris details these and the FIDELIO results.